Acorda Therapeutics Cdt Stock
Pros and Cons of Acorda Therapeutics Cdt in the next few years
Pros
?
G***** c******* t* c**********
?
B****
?
M***** P*******
Cons
?
C******** o* t** e**********
?
S********** s********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Acorda Therapeutics Cdt vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Acorda Therapeutics Cdt | - | - | - | - | - | - | - |
Ardelyx Inc. | -4.590% | 0.305% | 18.209% | 119.818% | 25.121% | 26.877% | - |
Evolus Inc | 0.840% | 0.840% | 15.385% | 27.660% | 32.597% | 61.074% | - |
Salarius Pharmaceuticals Inc. | -6.190% | 3.684% | -7.075% | -65.439% | -29.009% | -98.470% | -99.993% |
Comments
Acorda Therapeutics, Inc. (NASDAQ: ACOR) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.
Show more
Ratings data for ACOR provided by MarketBeat
Acorda Therapeutics, Inc. (NASDAQ: ACOR) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.
Show more
Ratings data for ACOR provided by MarketBeat
Acorda Therapeutics, Inc. (NASDAQ: ACOR) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.
Show more
Ratings data for ACOR provided by MarketBeat